Advertisement

Multiple Myeloma

Multiple Myeloma in 2015: A Year for the Record Books

Few malignancies have received as much attention, in the way of newly approved drugs, as multiple myeloma did in 2015. In November alone, 3 new agents were approved, bringing the total...

Cost of Care

The 340B Drug Pricing Program: Background, Concerns, and Solutions

The 340B Drug Pricing Program was created by Congress through the Veterans Health Care Act of 1992 to allow some health-care entities—including safety-net providers...

Lung Cancer

Bevacizumab Plus Chemotherapy Fails to Prolong Survival in Early-Stage Lung Cancer

Overall survival in patients with surgically resected early-stage non–small cell lung cancer (NSCLC) did not improve with the addition of bevacizumab (Avastin) to chemotherapy...


Advertisement

More Top Stories

Prostate Cancer

A. Oliver Sartor, MD, on Advanced Prostate Cancer: Predicting Treatment Resistance

Multiple Myeloma

Multiple Myeloma in 2015: A Year for the Record Books

Few malignancies have received as much attention, in the way of newly approved drugs, as multiple myeloma did in 2015. In November alone, 3 new agents were approved, bringing the total to 4 for the year as part of a record 7 approvals and to 16 regulatory approvals over the past 12 years.

Speakers ...

Advertisement

World Cancer Day 2016: We Can. I Can.

Cancer will kill more than 8 million people worldwide this year, which is equivalent to the entire population of New York. Half of these will be people of working age (30–69 years old).

It has been estimated that the cost implications on world economies caused by cancer and the other...

Kidney Cancer

Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial

Expert Point of View: Paul Bunn, Jr, MD

Although the results for E1505 were negative, “overall survival and disease-free survival are not the only things we can learn from this trial,” said Paul Bunn, Jr, MD, Distinguished Professor in the Division of Medical Oncology at the University of Colorado, Denver, who formally discussed the...

Cost of Care

The 340B Drug Pricing Program: Background, Concerns, and Solutions

The 340B Drug Pricing Program was created by Congress through the Veterans Health Care Act of 1992 to allow some health-care entities—including safety-net providers with large shares of uninsured and low-income patients and other “covered entities”—to obtain drugs at discounted prices.1,2 Congress...

ASCO Names Cancer Advance of the Year: Immunotherapy

At a Capitol Hill briefing today, ASCO announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy—along with almost 60 other important cancer research advances—are described in ASCO's just-released report, Clinical Cancer Advances 2016: ASCO's...

Solid Tumors

Matthew Smith, MD, PhD on Bone Metastases: Treatment Update

Lung Cancer

Bevacizumab Plus Chemotherapy Fails to Prolong Survival in Early-Stage Lung Cancer

Overall survival in patients with surgically resected early-stage non–small cell lung cancer (NSCLC) did not improve with the addition of bevacizumab (Avastin) to chemotherapy, according to the findings of a study researchers have called a “top abstract” from the 16th World Conference on Lung...

Advertisement

American College of Physicians Issues Advice, Raises Questions About Best Practices for Hematuria as a Sign of Cancer

In some patients, blood in the urine, or hematuria, may be the only warning sign of cancer in the urinary tract. A new report from the American College of Physicians’ (ACP) High Value Care Task Force published by Nielsen et al in Annals of Internal Medicine issues advice for physicians on how ...